Xeris Biopharma Quarterly Balance Sheet
NASDAQ: XERSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xeris Biopharma financial position
As of Jun 30, 2026, Xeris Biopharma reported total assets of $411.9 million, up 23.1% from a year earlier against total liabilities of $421.6 million. Shareholders' equity was negative at -$9.7 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $121.7 million in cash and equivalents against $252.6 million of debt, a net debt position of $130.8 million.
The current ratio (current assets divided by current liabilities) was 1.45, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Xeris Biopharma balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 121.75M | 111.75M | 111.04M | 91.60M | 59.28M | 58.44M | 71.62M | 59.23M | 57.60M | 62.69M | 67.45M | 46.14M |
| Short-Term Investments | — | — | — | — | — | — | 0 | 10.17M | 19.96M | 24.66M | 5.00M | 19.83M |
| Receivables | 58.10M | 56.30M | 51.05M | 53.75M | 53.05M | 46.33M | 40.41M | 41.14M | 42.44M | 37.41M | 39.20M | 45.97M |
| Inventory | 80.93M | 74.23M | 68.67M | 67.46M | 67.28M | 52.69M | 48.17M | 45.12M | 42.98M | 40.88M | 38.84M | 38.14M |
| Total Current Assets | 274.76M | 251.68M | 240.31M | 224.02M | 185.58M | 163.49M | 167.66M | 162.80M | 170.34M | 173.28M | 156.26M | 158.05M |
| Property, Plant & Equipment | 4.83M | 5.03M | 4.95M | 4.95M | 5.28M | 5.26M | 5.56M | 5.61M | 5.83M | 5.78M | 5.97M | 6.18M |
| Goodwill | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M |
| Intangible Assets | 82.66M | 85.37M | 88.08M | 90.79M | 93.50M | 96.21M | 98.92M | 101.63M | 104.34M | 107.05M | 109.76M | 112.47M |
| Total Assets | 411.90M | 392.01M | 383.53M | 370.19M | 334.69M | 315.45M | 323.06M | 321.10M | 331.73M | 336.62M | 322.60M | 327.78M |
| Accounts Payable | 9.34M | 11.47M | 3.08M | 6.53M | 9.46M | 6.35M | 2.29M | 7.45M | 5.80M | 7.09M | 11.56M | 12.08M |
| Short-Term Debt | 63.78M | — | 0 | 0 | 0 | 11.96M | 15.10M | 15.06M | — | — | 0 | — |
| Total Current Liabilities | 189.57M | 118.59M | 109.57M | 116.20M | 95.17M | 95.07M | 100.44M | 91.01M | 75.49M | 73.08M | 95.19M | 87.04M |
| Long-Term Debt | 188.81M | 221.22M | 220.34M | 219.47M | 218.63M | 217.81M | 217.01M | 216.23M | 230.48M | 229.67M | 190.93M | 190.42M |
| Total Liabilities | 421.64M | 379.00M | 369.84M | 371.05M | 353.99M | 350.58M | 352.68M | 349.43M | 351.02M | 345.79M | 329.38M | 323.92M |
| Shareholders' Equity | -9.73M | 13.01M | 13.69M | -861.00K | -19.30M | -35.13M | -29.61M | -28.32M | -19.29M | -9.18M | -6.78M | 3.87M |
| Retained Earnings | -700.17M | -669.07M | -671.31M | -682.39M | -683.01M | -681.08M | -671.86M | -666.75M | -651.01M | -636.00M | -617.02M | -603.63M |
| Total Debt | 252.59M | 221.22M | 220.34M | 219.47M | 218.63M | 229.76M | 232.11M | 231.28M | 230.48M | 229.67M | 190.93M | 190.42M |
| Net Cash (Debt) | -130.84M | -109.47M | -109.29M | -127.87M | -159.34M | -171.32M | -160.49M | -161.88M | -152.91M | -142.32M | -118.48M | -124.45M |
| Shares Outstanding | 173.59M | 172.56M | 166.22M | 165.53M | 161.22M | 156.01M | 149.43M | 149.00M | 148.94M | 148.22M | 138.13M | 138.07M |
This table shows 12 quarterly periods of Xeris Biopharma's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow XERS's reporting calendar. What is a balance sheet?